WO1999023075A1 - Ortho-hydroxypyridinone derivatives as iron chelating and antioxidant agents - Google Patents
Ortho-hydroxypyridinone derivatives as iron chelating and antioxidant agents Download PDFInfo
- Publication number
- WO1999023075A1 WO1999023075A1 PCT/GB1998/003244 GB9803244W WO9923075A1 WO 1999023075 A1 WO1999023075 A1 WO 1999023075A1 GB 9803244 W GB9803244 W GB 9803244W WO 9923075 A1 WO9923075 A1 WO 9923075A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound according
- alkyl
- methyl
- hydroxy
- butyl
- Prior art date
Links
- 239000003963 antioxidant agent Substances 0.000 title claims description 28
- 239000000797 iron chelating agent Substances 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 180
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 67
- 230000036542 oxidative stress Effects 0.000 claims abstract description 30
- 238000011282 treatment Methods 0.000 claims abstract description 26
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 17
- 125000001183 hydrocarbyl group Chemical group 0.000 claims abstract description 14
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 10
- 150000003839 salts Chemical class 0.000 claims abstract description 8
- 229910052717 sulfur Inorganic materials 0.000 claims abstract description 8
- 238000000034 method Methods 0.000 claims description 42
- 230000003078 antioxidant effect Effects 0.000 claims description 26
- 235000006708 antioxidants Nutrition 0.000 claims description 26
- 208000006011 Stroke Diseases 0.000 claims description 22
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 21
- 230000004792 oxidative damage Effects 0.000 claims description 16
- 210000003169 central nervous system Anatomy 0.000 claims description 10
- -1 hydroxy-substituted phenyl ring Chemical group 0.000 claims description 9
- 208000024827 Alzheimer disease Diseases 0.000 claims description 8
- 206010008120 Cerebral ischaemia Diseases 0.000 claims description 8
- 208000012902 Nervous system disease Diseases 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 7
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 6
- 238000001727 in vivo Methods 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- 230000009529 traumatic brain injury Effects 0.000 claims description 6
- 206010028980 Neoplasm Diseases 0.000 claims description 5
- 208000018737 Parkinson disease Diseases 0.000 claims description 5
- 230000002490 cerebral effect Effects 0.000 claims description 5
- 230000000302 ischemic effect Effects 0.000 claims description 5
- 206010003591 Ataxia Diseases 0.000 claims description 4
- 102000004190 Enzymes Human genes 0.000 claims description 4
- 108090000790 Enzymes Proteins 0.000 claims description 4
- 208000023105 Huntington disease Diseases 0.000 claims description 4
- 102000019197 Superoxide Dismutase Human genes 0.000 claims description 4
- 108010012715 Superoxide dismutase Proteins 0.000 claims description 4
- 230000001154 acute effect Effects 0.000 claims description 4
- 229910052799 carbon Inorganic materials 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 229910052739 hydrogen Inorganic materials 0.000 claims description 4
- 238000000338 in vitro Methods 0.000 claims description 4
- 208000001286 intracranial vasospasm Diseases 0.000 claims description 4
- 201000006417 multiple sclerosis Diseases 0.000 claims description 4
- 208000026072 Motor neurone disease Diseases 0.000 claims description 3
- 230000001684 chronic effect Effects 0.000 claims description 3
- 230000003834 intracellular effect Effects 0.000 claims description 3
- 208000005264 motor neuron disease Diseases 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 3
- 208000020431 spinal cord injury Diseases 0.000 claims description 3
- 238000002560 therapeutic procedure Methods 0.000 claims description 3
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 2
- 206010022998 Irritability Diseases 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 230000003244 pro-oxidative effect Effects 0.000 claims 2
- MXBCYQUALCBQIJ-RYVPXURESA-N (8s,9s,10r,13s,14s,17r)-13-ethyl-17-ethynyl-11-methylidene-1,2,3,6,7,8,9,10,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-ol;(8r,9s,13s,14s,17r)-17-ethynyl-13-methyl-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthrene-3,17-diol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1.C1CC[C@@H]2[C@H]3C(=C)C[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 MXBCYQUALCBQIJ-RYVPXURESA-N 0.000 claims 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 claims 1
- 241000223109 Trypanosoma cruzi Species 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 238000010348 incorporation Methods 0.000 claims 1
- 241000894007 species Species 0.000 claims 1
- 230000000654 trypanocidal effect Effects 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 abstract description 3
- 238000006243 chemical reaction Methods 0.000 description 36
- 239000000243 solution Substances 0.000 description 34
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 33
- 239000000047 product Substances 0.000 description 31
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 25
- 239000007787 solid Substances 0.000 description 25
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 24
- 239000000203 mixture Substances 0.000 description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 22
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 18
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 17
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 16
- JDNTWHVOXJZDSN-UHFFFAOYSA-N iodoacetic acid Chemical compound OC(=O)CI JDNTWHVOXJZDSN-UHFFFAOYSA-N 0.000 description 15
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 14
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 14
- 238000004587 chromatography analysis Methods 0.000 description 13
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- 239000002585 base Substances 0.000 description 12
- 229910052681 coesite Inorganic materials 0.000 description 12
- 229910052906 cristobalite Inorganic materials 0.000 description 12
- 239000000377 silicon dioxide Substances 0.000 description 12
- 229910052682 stishovite Inorganic materials 0.000 description 12
- 229910052905 tridymite Inorganic materials 0.000 description 12
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 11
- 210000004556 brain Anatomy 0.000 description 11
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 10
- 150000003254 radicals Chemical class 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 9
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 8
- HQABUPZFAYXKJW-UHFFFAOYSA-N butan-1-amine Chemical compound CCCCN HQABUPZFAYXKJW-UHFFFAOYSA-N 0.000 description 8
- 125000004122 cyclic group Chemical group 0.000 description 8
- 230000003859 lipid peroxidation Effects 0.000 description 8
- 239000003921 oil Substances 0.000 description 8
- 235000019198 oils Nutrition 0.000 description 8
- 238000010992 reflux Methods 0.000 description 8
- 239000003855 balanced salt solution Substances 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 7
- 230000000324 neuroprotective effect Effects 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- LQDVCPYRCOKNMV-UHFFFAOYSA-N 2-methyl-3-phenylmethoxypyran-4-one Chemical compound O1C=CC(=O)C(OCC=2C=CC=CC=2)=C1C LQDVCPYRCOKNMV-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 239000012267 brine Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 235000019439 ethyl acetate Nutrition 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 6
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 5
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 5
- 229910052742 iron Inorganic materials 0.000 description 5
- 230000003902 lesion Effects 0.000 description 5
- 239000012280 lithium aluminium hydride Substances 0.000 description 5
- 210000002569 neuron Anatomy 0.000 description 5
- 239000008188 pellet Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- GGOZGYRTNQBSSA-UHFFFAOYSA-N pyridine-2,3-diol Chemical compound OC1=CC=CN=C1O GGOZGYRTNQBSSA-UHFFFAOYSA-N 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 4
- QMMFVYPAHWMCMS-UHFFFAOYSA-N Dimethyl sulfide Chemical compound CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 4
- TZXKOCQBRNJULO-UHFFFAOYSA-N Ferriprox Chemical compound CC1=C(O)C(=O)C=CN1C TZXKOCQBRNJULO-UHFFFAOYSA-N 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 150000001299 aldehydes Chemical class 0.000 description 4
- 239000007900 aqueous suspension Substances 0.000 description 4
- 125000003118 aryl group Chemical group 0.000 description 4
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 4
- 229910000085 borane Inorganic materials 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 210000000782 cerebellar granule cell Anatomy 0.000 description 4
- 229960003266 deferiprone Drugs 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 230000003389 potentiating effect Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 125000001424 substituent group Chemical group 0.000 description 4
- LKIMDXQLHFCXQF-UHFFFAOYSA-N 3-methoxy-1h-pyridin-2-one Chemical compound COC1=CC=CN=C1O LKIMDXQLHFCXQF-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 229920000858 Cyclodextrin Polymers 0.000 description 3
- 208000016988 Hemorrhagic Stroke Diseases 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 208000025966 Neurological disease Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 206010063837 Reperfusion injury Diseases 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 150000001336 alkenes Chemical class 0.000 description 3
- 125000003545 alkoxy group Chemical group 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 3
- 244000309464 bull Species 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 238000009833 condensation Methods 0.000 description 3
- 230000005494 condensation Effects 0.000 description 3
- BEPAFCGSDWSTEL-UHFFFAOYSA-N dimethyl malonate Chemical compound COC(=O)CC(=O)OC BEPAFCGSDWSTEL-UHFFFAOYSA-N 0.000 description 3
- 150000002009 diols Chemical class 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- FTQWRYSLUYAIRQ-UHFFFAOYSA-N n-[(octadecanoylamino)methyl]octadecanamide Chemical compound CCCCCCCCCCCCCCCCCC(=O)NCNC(=O)CCCCCCCCCCCCCCCCC FTQWRYSLUYAIRQ-UHFFFAOYSA-N 0.000 description 3
- LYGJENNIWJXYER-UHFFFAOYSA-N nitromethane Chemical compound C[N+]([O-])=O LYGJENNIWJXYER-UHFFFAOYSA-N 0.000 description 3
- 230000001590 oxidative effect Effects 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 239000002530 phenolic antioxidant Substances 0.000 description 3
- 150000003141 primary amines Chemical class 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- XQXGMYCGBQVFTD-UHFFFAOYSA-N 1-[(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydrochromen-2-yl)methyl]-2-methyl-3-phenylmethoxypyridin-4-one Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)CN(C=1C)C=CC(=O)C=1OCC1=CC=CC=C1 XQXGMYCGBQVFTD-UHFFFAOYSA-N 0.000 description 2
- GOCYHWSJDMJUHW-UHFFFAOYSA-N 1-[2-(3,5-dimethoxy-4-phenylmethoxyphenyl)ethyl]-2-methyl-3-phenylmethoxypyridin-4-one Chemical compound C=1C(OC)=C(OCC=2C=CC=CC=2)C(OC)=CC=1CCN(C=1C)C=CC(=O)C=1OCC1=CC=CC=C1 GOCYHWSJDMJUHW-UHFFFAOYSA-N 0.000 description 2
- WVKZQEBLOISVIN-UHFFFAOYSA-N 1-[2-(3,5-ditert-butyl-4-hydroxyphenyl)ethyl]-2-methyl-3-phenylmethoxypyridin-4-one Chemical compound O=C1C=CN(CCC=2C=C(C(O)=C(C=2)C(C)(C)C)C(C)(C)C)C(C)=C1OCC1=CC=CC=C1 WVKZQEBLOISVIN-UHFFFAOYSA-N 0.000 description 2
- YWELVSNRSUPTML-UHFFFAOYSA-N 1-[2-(5-hydroxy-4,6,7-trimethyl-2,3-dihydro-1-benzofuran-2-yl)ethyl]-2-methyl-3-phenylmethoxypyridin-4-one Chemical compound O1C2=C(C)C(C)=C(O)C(C)=C2CC1CCN(C=1C)C=CC(=O)C=1OCC1=CC=CC=C1 YWELVSNRSUPTML-UHFFFAOYSA-N 0.000 description 2
- GPJHFALXPVBZGR-UHFFFAOYSA-N 1-[3-(3,5-ditert-butyl-4-hydroxyphenyl)propyl]-2-methyl-3-phenylmethoxypyridin-4-one Chemical compound O=C1C=CN(CCCC=2C=C(C(O)=C(C=2)C(C)(C)C)C(C)(C)C)C(C)=C1OCC1=CC=CC=C1 GPJHFALXPVBZGR-UHFFFAOYSA-N 0.000 description 2
- GEBVAOQWFMZAOB-UHFFFAOYSA-N 1-[3-(4-hydroxy-3,5-dimethoxyphenyl)propyl]-2-methyl-3-phenylmethoxypyridin-4-one Chemical compound COC1=C(O)C(OC)=CC(CCCN2C(=C(OCC=3C=CC=CC=3)C(=O)C=C2)C)=C1 GEBVAOQWFMZAOB-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- LTMRRSWNXVJMBA-UHFFFAOYSA-L 2,2-diethylpropanedioate Chemical compound CCC(CC)(C([O-])=O)C([O-])=O LTMRRSWNXVJMBA-UHFFFAOYSA-L 0.000 description 2
- JDXKBZKHIHLMCE-UHFFFAOYSA-N 2,6-ditert-butyl-4-(3-iodopropyl)phenol Chemical compound CC(C)(C)C1=CC(CCCI)=CC(C(C)(C)C)=C1O JDXKBZKHIHLMCE-UHFFFAOYSA-N 0.000 description 2
- HQLBETRRBSCPSS-UHFFFAOYSA-N 2-(2,3,5-trimethyl-4-phenylmethoxyphenoxy)acetamide Chemical compound CC1=CC(OCC(N)=O)=C(C)C(C)=C1OCC1=CC=CC=C1 HQLBETRRBSCPSS-UHFFFAOYSA-N 0.000 description 2
- GPDBDORYQTWRFO-UHFFFAOYSA-N 2-(2,3,5-trimethyl-4-phenylmethoxyphenoxy)ethanamine Chemical compound CC1=CC(OCCN)=C(C)C(C)=C1OCC1=CC=CC=C1 GPDBDORYQTWRFO-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
- YMXJIXXBIBPHGM-UHFFFAOYSA-N 2-methyl-3-phenylmethoxy-1-[2-(2,3,5-trimethyl-4-phenylmethoxyphenoxy)ethyl]pyridin-4-one Chemical compound CC=1C(C)=C(OCC=2C=CC=CC=2)C(C)=CC=1OCCN(C=1C)C=CC(=O)C=1OCC1=CC=CC=C1 YMXJIXXBIBPHGM-UHFFFAOYSA-N 0.000 description 2
- RVBUGGBMJDPOST-UHFFFAOYSA-N 2-thiobarbituric acid Chemical compound O=C1CC(=O)NC(=S)N1 RVBUGGBMJDPOST-UHFFFAOYSA-N 0.000 description 2
- DOZRDZLFLOODMB-UHFFFAOYSA-N 3,5-di-tert-Butyl-4-hydroxybenzaldehyde Chemical compound CC(C)(C)C1=CC(C=O)=CC(C(C)(C)C)=C1O DOZRDZLFLOODMB-UHFFFAOYSA-N 0.000 description 2
- FJDLQLIRZFKEKJ-UHFFFAOYSA-N 3-(3,5-ditert-butyl-4-hydroxyphenyl)propanamide Chemical compound CC(C)(C)C1=CC(CCC(N)=O)=CC(C(C)(C)C)=C1O FJDLQLIRZFKEKJ-UHFFFAOYSA-N 0.000 description 2
- WPMYUUITDBHVQZ-UHFFFAOYSA-N 3-(3,5-ditert-butyl-4-hydroxyphenyl)propanoic acid Chemical compound CC(C)(C)C1=CC(CCC(O)=O)=CC(C(C)(C)C)=C1O WPMYUUITDBHVQZ-UHFFFAOYSA-N 0.000 description 2
- ZCUUVWCJGRQCMZ-UHFFFAOYSA-N 3-hydroxypyridin-4(1H)-one Chemical compound OC1=CC=NC=C1O ZCUUVWCJGRQCMZ-UHFFFAOYSA-N 0.000 description 2
- LUWJFAGOLNUTBA-UHFFFAOYSA-N 4-(3-aminopropyl)-2,6-ditert-butylphenol Chemical compound CC(C)(C)C1=CC(CCCN)=CC(C(C)(C)C)=C1O LUWJFAGOLNUTBA-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 0 C*c(c(C)c1C)cc(C)c1O Chemical compound C*c(c(C)c1C)cc(C)c1O 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 2
- QDHHCQZDFGDHMP-UHFFFAOYSA-N Chloramine Chemical compound ClN QDHHCQZDFGDHMP-UHFFFAOYSA-N 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 208000005189 Embolism Diseases 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical group OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- 201000011240 Frontotemporal dementia Diseases 0.000 description 2
- 208000032382 Ischaemic stroke Diseases 0.000 description 2
- 238000000023 Kugelrohr distillation Methods 0.000 description 2
- 229910010084 LiAlH4 Inorganic materials 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Chemical group 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 102000019259 Succinate Dehydrogenase Human genes 0.000 description 2
- 108010012901 Succinate Dehydrogenase Proteins 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 2
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 2
- 208000032109 Transient ischaemic attack Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 125000002015 acyclic group Chemical group 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 230000029936 alkylation Effects 0.000 description 2
- 238000005804 alkylation reaction Methods 0.000 description 2
- 238000007112 amidation reaction Methods 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 150000001412 amines Chemical group 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- KVNRLNFWIYMESJ-UHFFFAOYSA-N butyronitrile Chemical compound CCCC#N KVNRLNFWIYMESJ-UHFFFAOYSA-N 0.000 description 2
- 230000004094 calcium homeostasis Effects 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 239000013522 chelant Substances 0.000 description 2
- OEUUFNIKLCFNLN-LLVKDONJSA-N chembl432481 Chemical compound OC(=O)[C@@]1(C)CSC(C=2C(=CC(O)=CC=2)O)=N1 OEUUFNIKLCFNLN-LLVKDONJSA-N 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- MLIREBYILWEBDM-UHFFFAOYSA-N cyanoacetic acid Chemical compound OC(=O)CC#N MLIREBYILWEBDM-UHFFFAOYSA-N 0.000 description 2
- 229940097362 cyclodextrins Drugs 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 230000001066 destructive effect Effects 0.000 description 2
- MHDVGSVTJDSBDK-UHFFFAOYSA-N dibenzyl ether Chemical compound C=1C=CC=CC=1COCC1=CC=CC=C1 MHDVGSVTJDSBDK-UHFFFAOYSA-N 0.000 description 2
- NGUGYWYQFCZHTR-UHFFFAOYSA-N dimethyl 2-[(3,5-ditert-butyl-4-hydroxyphenyl)methyl]propanedioate Chemical compound COC(=O)C(C(=O)OC)CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NGUGYWYQFCZHTR-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 238000007429 general method Methods 0.000 description 2
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- 150000004820 halides Chemical class 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- LIAWOTKNAVAKCX-UHFFFAOYSA-N hydrazine;dihydrochloride Chemical compound Cl.Cl.NN LIAWOTKNAVAKCX-UHFFFAOYSA-N 0.000 description 2
- 239000003701 inert diluent Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229940118019 malondialdehyde Drugs 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000000155 melt Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 150000002739 metals Chemical class 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- 210000001577 neostriatum Anatomy 0.000 description 2
- 230000016273 neuron death Effects 0.000 description 2
- 230000007135 neurotoxicity Effects 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 230000008816 organ damage Effects 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- 239000010452 phosphate Chemical group 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- DKORSYDQYFVQNS-UHFFFAOYSA-N propyl methanesulfonate Chemical compound CCCOS(C)(=O)=O DKORSYDQYFVQNS-UHFFFAOYSA-N 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 230000004224 protection Effects 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 239000003642 reactive oxygen metabolite Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000001117 sulphuric acid Substances 0.000 description 2
- 235000011149 sulphuric acid Nutrition 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- GFXLQCGVBUWBHF-WLHGVMLRSA-M (e)-3-oxoprop-1-en-1-olate;tetrabutylazanium Chemical compound [O-]\C=C\C=O.CCCC[N+](CCCC)(CCCC)CCCC GFXLQCGVBUWBHF-WLHGVMLRSA-M 0.000 description 1
- XCGFDWWTWLWTRO-UHFFFAOYSA-N 1-[2-(3,5-ditert-butyl-4-hydroxyphenyl)sulfanylethyl]-2-methyl-3-phenylmethoxypyridin-4-one Chemical compound O=C1C=CN(CCSC=2C=C(C(O)=C(C=2)C(C)(C)C)C(C)(C)C)C(C)=C1OCC1=CC=CC=C1 XCGFDWWTWLWTRO-UHFFFAOYSA-N 0.000 description 1
- VUWMXICRCBOLKW-UHFFFAOYSA-N 1-[2-[(3,5-ditert-butyl-4-hydroxyphenyl)methyl]-3-(3-hydroxy-2-methyl-4-oxopyridin-1-yl)propyl]-3-hydroxy-2-methylpyridin-4-one Chemical compound CC1=C(O)C(=O)C=CN1CC(CN1C(=C(O)C(=O)C=C1)C)CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 VUWMXICRCBOLKW-UHFFFAOYSA-N 0.000 description 1
- LQHULTSUXRVIJT-UHFFFAOYSA-N 1-[4-(3,5-ditert-butyl-4-hydroxyphenyl)butyl]-2-methyl-3-phenylmethoxypyridin-4-one Chemical compound O=C1C=CN(CCCCC=2C=C(C(O)=C(C=2)C(C)(C)C)C(C)(C)C)C(C)=C1OCC1=CC=CC=C1 LQHULTSUXRVIJT-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- VFNKZQNIXUFLBC-UHFFFAOYSA-N 2',7'-dichlorofluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(Cl)=C(O)C=C1OC1=C2C=C(Cl)C(O)=C1 VFNKZQNIXUFLBC-UHFFFAOYSA-N 0.000 description 1
- HARBYIUXNNCKAN-UHFFFAOYSA-N 2,3,5-trimethyl-4-phenylmethoxyphenol Chemical compound CC1=CC(O)=C(C)C(C)=C1OCC1=CC=CC=C1 HARBYIUXNNCKAN-UHFFFAOYSA-N 0.000 description 1
- KPYNPYLYIYBHEI-UHFFFAOYSA-N 2,6-ditert-butyl-4-(3-hydroxypropyl)phenol Chemical compound CC(C)(C)C1=CC(CCCO)=CC(C(C)(C)C)=C1O KPYNPYLYIYBHEI-UHFFFAOYSA-N 0.000 description 1
- NFVMNXZFSKGLDR-UHFFFAOYSA-N 2,6-ditert-butyl-4-sulfanylphenol Chemical class CC(C)(C)C1=CC(S)=CC(C(C)(C)C)=C1O NFVMNXZFSKGLDR-UHFFFAOYSA-N 0.000 description 1
- MAMLNDNAXXWPTI-UHFFFAOYSA-N 2-(2-aminoethyl)-4,6,7-trimethyl-2,3-dihydro-1-benzofuran-5-ol Chemical compound CC1=C(O)C(C)=C2CC(CCN)OC2=C1C MAMLNDNAXXWPTI-UHFFFAOYSA-N 0.000 description 1
- BUJBXOZJFOWVCR-UHFFFAOYSA-N 2-(3,5-dimethoxy-4-phenylmethoxyphenyl)ethanamine Chemical compound COC1=CC(CCN)=CC(OC)=C1OCC1=CC=CC=C1 BUJBXOZJFOWVCR-UHFFFAOYSA-N 0.000 description 1
- PXEZTIWVRVSYOK-UHFFFAOYSA-N 2-(3,6-diacetyloxy-2,7-dichloro-9h-xanthen-9-yl)benzoic acid Chemical compound C1=2C=C(Cl)C(OC(=O)C)=CC=2OC2=CC(OC(C)=O)=C(Cl)C=C2C1C1=CC=CC=C1C(O)=O PXEZTIWVRVSYOK-UHFFFAOYSA-N 0.000 description 1
- KRNBXCXRAYRRRP-UHFFFAOYSA-N 2-(aminomethyl)-2,5,7,8-tetramethyl-3,4-dihydrochromen-6-ol Chemical compound O1C(C)(CN)CCC2=C1C(C)=C(C)C(O)=C2C KRNBXCXRAYRRRP-UHFFFAOYSA-N 0.000 description 1
- VHEWPJDCOSATTD-UHFFFAOYSA-N 3-(3,5-ditert-butyl-4-hydroxyphenyl)propyl methanesulfonate Chemical compound CC(C)(C)C1=CC(CCCOS(C)(=O)=O)=CC(C(C)(C)C)=C1O VHEWPJDCOSATTD-UHFFFAOYSA-N 0.000 description 1
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 1
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 1
- FMOAICBJDCGMMD-UHFFFAOYSA-N 3-hydroxy-1h-pyridin-2-one;iron Chemical compound [Fe].OC1=CC=CNC1=O FMOAICBJDCGMMD-UHFFFAOYSA-N 0.000 description 1
- NFDSTZLSXAFOGV-UHFFFAOYSA-N 4-(2-aminoethylsulfanyl)-2,6-ditert-butylphenol Chemical compound CC(C)(C)C1=CC(SCCN)=CC(C(C)(C)C)=C1O NFDSTZLSXAFOGV-UHFFFAOYSA-N 0.000 description 1
- GSVYQKPSPVNUNT-UHFFFAOYSA-N 4-(3-aminopropyl)-2,6-dimethoxyphenol Chemical compound COC1=CC(CCCN)=CC(OC)=C1O GSVYQKPSPVNUNT-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- YEOQCOZNFXPHHY-UHFFFAOYSA-N 4-(bromomethyl)-2,6-ditert-butylphenol Chemical compound CC(C)(C)C1=CC(CBr)=CC(C(C)(C)C)=C1O YEOQCOZNFXPHHY-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 230000002407 ATP formation Effects 0.000 description 1
- 208000005452 Acute intermittent porphyria Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 229910015845 BBr3 Inorganic materials 0.000 description 1
- 229910015844 BCl3 Inorganic materials 0.000 description 1
- 206010048962 Brain oedema Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- IJIBLLILIDMCDO-UHFFFAOYSA-N CC(C)(C)c(cc(C(CN(C=CC1=O)C(C)=C1O)CN(C=CC1=O)C(C)=C1O)cc1C(C)(C)C)c1O Chemical compound CC(C)(C)c(cc(C(CN(C=CC1=O)C(C)=C1O)CN(C=CC1=O)C(C)=C1O)cc1C(C)(C)C)c1O IJIBLLILIDMCDO-UHFFFAOYSA-N 0.000 description 1
- QJVTZMNNJAMBSQ-UHFFFAOYSA-N CC(C)(C)c1cc(CCCN(C=CC=C2O)C2=O)cc(C(C)(C)C)c1O Chemical compound CC(C)(C)c1cc(CCCN(C=CC=C2O)C2=O)cc(C(C)(C)C)c1O QJVTZMNNJAMBSQ-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 206010008132 Cerebral thrombosis Diseases 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- 201000010374 Down Syndrome Diseases 0.000 description 1
- 206010013647 Drowning Diseases 0.000 description 1
- 239000004150 EU approved colour Substances 0.000 description 1
- 206010014612 Encephalitis viral Diseases 0.000 description 1
- 244000166102 Eucalyptus leucoxylon Species 0.000 description 1
- 235000004694 Eucalyptus leucoxylon Nutrition 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- BJJXHLWLUDYTGC-ANULTFPQSA-N Gestrinone Chemical compound C1CC(=O)C=C2CC[C@@H]([C@H]3[C@@](CC)([C@](CC3)(O)C#C)C=C3)C3=C21 BJJXHLWLUDYTGC-ANULTFPQSA-N 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 208000022461 Glomerular disease Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000018899 Glutamate Receptors Human genes 0.000 description 1
- 108010027915 Glutamate Receptors Proteins 0.000 description 1
- 102000006587 Glutathione peroxidase Human genes 0.000 description 1
- 108700016172 Glutathione peroxidases Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 208000013875 Heart injury Diseases 0.000 description 1
- 208000018565 Hemochromatosis Diseases 0.000 description 1
- 208000032759 Hemolytic-Uremic Syndrome Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 238000007167 Hofmann rearrangement reaction Methods 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 206010022562 Intermittent claudication Diseases 0.000 description 1
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 1
- 108090000862 Ion Channels Proteins 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 230000010699 Iron Chelating Activity Effects 0.000 description 1
- 206010065973 Iron Overload Diseases 0.000 description 1
- 239000002211 L-ascorbic acid Substances 0.000 description 1
- 235000000069 L-ascorbic acid Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010024238 Leptospirosis Diseases 0.000 description 1
- 208000009829 Lewy Body Disease Diseases 0.000 description 1
- 201000002832 Lewy body dementia Diseases 0.000 description 1
- 238000005684 Liebig rearrangement reaction Methods 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 206010027260 Meningitis viral Diseases 0.000 description 1
- 208000001089 Multiple system atrophy Diseases 0.000 description 1
- 101100010166 Mus musculus Dok3 gene Proteins 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 1
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 1
- 238000007126 N-alkylation reaction Methods 0.000 description 1
- UBQYURCVBFRUQT-UHFFFAOYSA-N N-benzoyl-Ferrioxamine B Chemical compound CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN UBQYURCVBFRUQT-UHFFFAOYSA-N 0.000 description 1
- 229940099433 NMDA receptor antagonist Drugs 0.000 description 1
- 206010028923 Neonatal asphyxia Diseases 0.000 description 1
- 208000037212 Neonatal hypoxic and ischemic brain injury Diseases 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 102000015336 Nerve Growth Factor Human genes 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 208000000609 Pick Disease of the Brain Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000723554 Pontia occidentalis Species 0.000 description 1
- 206010036182 Porphyria acute Diseases 0.000 description 1
- 206010036312 Post-traumatic epilepsy Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000024777 Prion disease Diseases 0.000 description 1
- 239000007868 Raney catalyst Substances 0.000 description 1
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 1
- 229910000564 Raney nickel Inorganic materials 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 208000020339 Spinal injury Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 description 1
- 208000002667 Subdural Hematoma Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 206010043391 Thalassaemia beta Diseases 0.000 description 1
- 208000002903 Thalassemia Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 102000007238 Transferrin Receptors Human genes 0.000 description 1
- 108010033576 Transferrin Receptors Proteins 0.000 description 1
- 206010044688 Trisomy 21 Diseases 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 201000004810 Vascular dementia Diseases 0.000 description 1
- 208000028207 Weil disease Diseases 0.000 description 1
- 238000006993 Weiss annulation reaction Methods 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 230000004103 aerobic respiration Effects 0.000 description 1
- 150000001298 alcohols Chemical group 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 125000005078 alkoxycarbonylalkyl group Chemical group 0.000 description 1
- 125000005093 alkyl carbonyl alkyl group Chemical group 0.000 description 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 1
- 150000001351 alkyl iodides Chemical class 0.000 description 1
- 230000002152 alkylating effect Effects 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 229960003318 alteplase Drugs 0.000 description 1
- 159000000013 aluminium salts Chemical class 0.000 description 1
- 125000004103 aminoalkyl group Chemical group 0.000 description 1
- 125000005097 aminocarbonylalkyl group Chemical group 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 125000005099 aryl alkyl carbonyl group Chemical group 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 125000005100 aryl amino carbonyl group Chemical group 0.000 description 1
- 125000005129 aryl carbonyl group Chemical group 0.000 description 1
- 125000005160 aryl oxy alkyl group Chemical group 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 125000004181 carboxyalkyl group Chemical group 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 238000013172 carotid endarterectomy Methods 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000007541 cellular toxicity Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 206010008129 cerebral palsy Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- KXZJHVJKXJLBKO-UHFFFAOYSA-N chembl1408157 Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=CC=1C1=CC=C(O)C=C1 KXZJHVJKXJLBKO-UHFFFAOYSA-N 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000013626 chemical specie Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- VXIVSQZSERGHQP-UHFFFAOYSA-N chloroacetamide Chemical compound NC(=O)CCl VXIVSQZSERGHQP-UHFFFAOYSA-N 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 229940125846 compound 25 Drugs 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- YKGMKSIHIVVYKY-UHFFFAOYSA-N dabrafenib mesylate Chemical compound CS(O)(=O)=O.S1C(C(C)(C)C)=NC(C=2C(=C(NS(=O)(=O)C=3C(=CC=CC=3F)F)C=CC=2)F)=C1C1=CC=NC(N)=N1 YKGMKSIHIVVYKY-UHFFFAOYSA-N 0.000 description 1
- 230000006196 deacetylation Effects 0.000 description 1
- 238000003381 deacetylation reaction Methods 0.000 description 1
- 229960000958 deferoxamine Drugs 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 125000004985 dialkyl amino alkyl group Chemical group 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- 125000004473 dialkylaminocarbonyl group Chemical group 0.000 description 1
- FHIVAFMUCKRCQO-UHFFFAOYSA-N diazinon Chemical compound CCOP(=S)(OCC)OC1=CC(C)=NC(C(C)C)=N1 FHIVAFMUCKRCQO-UHFFFAOYSA-N 0.000 description 1
- NPOMSUOUAZCMBL-UHFFFAOYSA-N dichloromethane;ethoxyethane Chemical compound ClCCl.CCOCC NPOMSUOUAZCMBL-UHFFFAOYSA-N 0.000 description 1
- 150000005690 diesters Chemical class 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- DEQYTNZJHKPYEZ-UHFFFAOYSA-N ethyl acetate;heptane Chemical compound CCOC(C)=O.CCCCCCC DEQYTNZJHKPYEZ-UHFFFAOYSA-N 0.000 description 1
- 231100000318 excitotoxic Toxicity 0.000 description 1
- 230000003492 excitotoxic effect Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229940074045 glyceryl distearate Drugs 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 230000034659 glycolysis Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- NAQMVNRVTILPCV-UHFFFAOYSA-N hexane-1,6-diamine Chemical compound NCCCCCCN NAQMVNRVTILPCV-UHFFFAOYSA-N 0.000 description 1
- 230000009097 homeostatic mechanism Effects 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Chemical group OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical compound [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- JGPMMRGNQUBGND-UHFFFAOYSA-N idebenone Chemical compound COC1=C(OC)C(=O)C(CCCCCCCCCCO)=C(C)C1=O JGPMMRGNQUBGND-UHFFFAOYSA-N 0.000 description 1
- 229960004135 idebenone Drugs 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 231100000268 induced nephrotoxicity Toxicity 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 208000021156 intermittent vascular claudication Diseases 0.000 description 1
- 230000008810 intracellular oxidative stress Effects 0.000 description 1
- 230000006525 intracellular process Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 238000010630 lipid peroxidation (MDA) assay Methods 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000008263 liquid aerosol Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- WRIRWRKPLXCTFD-UHFFFAOYSA-N malonamide Chemical compound NC(=O)CC(N)=O WRIRWRKPLXCTFD-UHFFFAOYSA-N 0.000 description 1
- CUONGYYJJVDODC-UHFFFAOYSA-N malononitrile Chemical compound N#CCC#N CUONGYYJJVDODC-UHFFFAOYSA-N 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- OJURWUUOVGOHJZ-UHFFFAOYSA-N methyl 2-[(2-acetyloxyphenyl)methyl-[2-[(2-acetyloxyphenyl)methyl-(2-methoxy-2-oxoethyl)amino]ethyl]amino]acetate Chemical compound C=1C=CC=C(OC(C)=O)C=1CN(CC(=O)OC)CCN(CC(=O)OC)CC1=CC=CC=C1OC(C)=O OJURWUUOVGOHJZ-UHFFFAOYSA-N 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 229940053128 nerve growth factor Drugs 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000004112 neuroprotection Effects 0.000 description 1
- 239000004090 neuroprotective agent Substances 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- GYCKQBWUSACYIF-UHFFFAOYSA-N o-hydroxybenzoic acid ethyl ester Natural products CCOC(=O)C1=CC=CC=C1O GYCKQBWUSACYIF-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 229940006093 opthalmologic coloring agent diagnostic Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000010627 oxidative phosphorylation Effects 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 208000033300 perinatal asphyxia Diseases 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 201000002212 progressive supranuclear palsy Diseases 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical compound OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- GPKJTRJOBQGKQK-UHFFFAOYSA-N quinacrine Chemical compound C1=C(OC)C=C2C(NC(C)CCCN(CC)CC)=C(C=CC(Cl)=C3)C3=NC2=C1 GPKJTRJOBQGKQK-UHFFFAOYSA-N 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 208000007056 sickle cell anemia Diseases 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- MNWBNISUBARLIT-UHFFFAOYSA-N sodium cyanide Chemical compound [Na+].N#[C-] MNWBNISUBARLIT-UHFFFAOYSA-N 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 230000037351 starvation Effects 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical group [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000012956 testing procedure Methods 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000003104 tissue culture media Substances 0.000 description 1
- 229960000187 tissue plasminogen activator Drugs 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 125000005490 tosylate group Chemical group 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- FAQYAMRNWDIXMY-UHFFFAOYSA-N trichloroborane Chemical compound ClB(Cl)Cl FAQYAMRNWDIXMY-UHFFFAOYSA-N 0.000 description 1
- CPRPKIMXLHBUGA-UHFFFAOYSA-N triethyltin Chemical compound CC[Sn](CC)CC CPRPKIMXLHBUGA-UHFFFAOYSA-N 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 238000001665 trituration Methods 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 201000002498 viral encephalitis Diseases 0.000 description 1
- 201000010044 viral meningitis Diseases 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 239000003039 volatile agent Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/69—Two or more oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Definitions
- the present invention relates to compounds containing both ortho-hydroxypyridinone and oxygenated aryl functionalities, which possess the dual ability to chelate iron and 5 scavenge reactive oxygen species (ROS).
- the invention relates to specific compounds containing a 3-hydroxy-4(lH)-pyridinone or a 3-hydroxy-2(lH)-pyridinone iron chelating moiety as well as a phenolic antioxidant moiety.
- the present invention also relates to the synthesis of such compounds, to pharmaceutical preparations comprising such compounds and to the use of such compounds in the treatment and o prophylaxis of conditions resulting in oxidative stress, particularly oxidative damage to the central nervous system.
- Stroke is the third leading cause of death in major industrialised countries and the commonest cause of permanent disability (Hunter et al, Trends in Pharmacological Sciences, 1995, 16, 123-128). Each year, in the US and Europe, approximately 1 million people suffer acute stroke (Dorman et al, CNS Drugs, 1996, 5, 457-474). Between 25% and 35% of these patients die within the first three weeks, and of the survivors 25% to 0 50%) will be totally dependant on family or institutional care for the rest of their lives.
- Stroke is defined as an interruption of the blood flow to the brain or leakage of blood out of the brain, resulting in oxygen deprivation (ischaemia) and subsequent neuronal cell 0 death. Strokes can be divided into two classes, ischaemic and haemorragic. The former accounts for approximately 83% of all strokes and is caused by thrombosis (65%o) and/or detachment of a previously formed clot (embolus, 18%>). Haemorrhagic strokes, which account for the remaining 17%> of all strokes, can be subdivided into subarachnoid haemorrhage (7%) and cerebral haemorrhage (10%).
- lipid peroxidation lipid peroxidation
- OH hydroxyl radical
- Exposure to free radicals is a natural consequence of aerobic respiration, to which the human body possesses a variety of natural antioxidant mechanisms. However, during pathological conditions such as stroke homeostatic mechanisms break down, and the balance between the generation of free radicals and natural antioxidant defences is shifted, resulting in a state of oxidative stress (Beal M.F., Ann. Neurol., 1995, 31, 119- 130; Gerlach et al, J. Neurochem., 1994, 63, 793-807).
- the iron chelator deferiprone (l,2-dimethyl-3-hydroxy-4(lH)-pyridinone) has also been shown to possess antioxidant properties.
- deferiprone to inhibit free radical formation has been disclosed by Kontochiorghes et al. (Free Rad. Res. Comms., 1986, 2, 115-124) and by Mostert et al (Free Rad. Res. Comms., 1987, 3, 379-388).
- the use of deferiprone in conjunction with an antioxidant is also disclosed in WO 94/03169 for use in the treatment of sickle cell disease, and by Antonius et al. (Circulation, 1989, 80, 158-164) for use in the prevention of postischemic cardiac injury.
- Deferiprone has recently been in clinical trials as a potential treatment for iron overload in thalassemia major, and has also been disclosed for the treatment of parasitic infections, anemia and Alzheimer's disease.
- Altepase ® tissue plasminogen activator, rTPA
- rTPA tissue plasminogen activator
- Therapeutic thrombolysis can, however, be complicated by a) systemic haemorrhage, b) intracerebral haemorrhage, c) distal embolism of a partially digested clot leading to secondary infarction and d) cerebral oedema secondary to reperfusion injury. It is, therefore, necessary to exclude the possibility of haemorrhagic stroke by computerised tomographic (CT) scanning of patients before administering Alteplase.
- CT computerised tomographic
- carotid endarterectomy is a surgical procedure for unblocking the carotid artery.
- both treatments have the potential to exacerbate and complicate the original injury, and neither treatment is neuroprotective nor universal for all types of stroke.
- a third treatment, the antioxidant idebenone is licensed for the treatment of stroke in Japan. There is therefore a large unmet medical need for an effective neuroprotective compound for the treatment of stroke.
- R 1 , R 2 and R 3 are independently selected from H and alkyl; wherein X is O, S, NR 4 or a direct bond, wherein R 4 is H or alkyl; wherein Z is a saturated hydrocarbyl chain comprising from 1 to 10 carbon atoms; wherein q is 1, 2 or 3, wherein if q is 2 or 3, then each A can be the same or different; wherein the or each R 5 is independently selected from H or alkyl; wherein the or each R 6 is independently selected from alkyl; wherein n is 1 to 5; wherein p is 0 to 4; and wherein the sum of n and p is less than 6, or a pharmaceutically acceptable salt thereof.
- the compounds of the present invention which have a combined antioxidant and iron-chelating activity can be used for treating oxidative stress, particularly oxidative damage to the central nervous system.
- the compounds of the present invention are surprisingly more effective in vitro, especially at low concentrations, than the simultaneous use of the separate hydroxypyridone iron-chelating compound and the phenolic antioxidant compound.
- alkyl means a branched or unbranched, cyclic or acyclic, saturated or unsaturated (e.g. alkenyl or alkynyl) hydrocarbyl radical.
- the alkyl group is preferably C 3 to C, 2 , more preferably C 5 to C, resume, more preferably C 5 to C 7 .
- the alkyl group is preferably C, to C 10 , more preferably C, to C 6 , more preferably methyl, ethyl, propyl, isopropyl, butyl, t-butyl, pentyl and iso-pentyl.
- alkyl groups may be substituted or unsubstituted. Where substituted, there will generally be 1 to 3 substituents present.
- Substituents may include carbon containing groups such as: alkyl, aryl, arylalkyl (e.g. substituted and unsubstituted phenyl, substituted and unsubstituted benzyl); halogen atoms and halogen containing groups such as haloalkyl (e.g. trifluoromethyl); oxygen containing groups such as alcohols (e.g. hydroxy, hydroxyalkyl, aryl(hydroxy)alkyl), ethers (e.g.
- aminocarbonyl e.g. aminocarbonyl, mono- or dialkylaminocarbonyl, aminocarbonylalkyl, mono- or dialkylaminocarbonylalkyl, arylaminocarbonyl
- nitrogen containing groups such as amines (e.g. amino, mono- or dialkylamino, aminoalkyl, mono- or dialkylaminoalkyl).
- alkoxy means alkyl-O-. Alkoxy substituent groups or alkoxy- containing substituent groups may be substituted by one or more alkyl groups.
- halogen means a fluorine, chlorine, bromine or iodine radical, preferably a fluorine or chlorine radical.
- the alkyl groups are either unsubstituted or substituted by substitution of a hydrogen atom with a group selected from OR 7 , OCOR 7 , COOR 7 , NHR 7 , NHCOR 7 and CONHR 7 wherein R 7 is H or alkyl.
- salts may be prepared from pharmaceutically acceptable non-toxic acids and bases including inorganic and organic acids and bases.
- acids include acetic, benzenesulfonic, benzoic, camphorsulfonic, citric, ethenesulfonic, dichloroacetic, furnaric, gluconic, glutamic, hippuric, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, mandelic, methanesulfonic, mucic, nitric, pamoic, pantothenic, phosphoric, succinic, sulfuric, tartaric, oxalic, p-toluenesulfonic and the like.
- hydrochloric, hydrobromic, phosphoric, sulfuric and methanesulfonic acids particularly preferred are hydrochloric, hydrobromic, phosphoric, sulfuric and methanesulfonic acids, and most particularly preferred is the methanesulfonate salt.
- Acceptable base salts include alkali metal (e.g. sodium, potassium), alkaline earth metal (e.g. calcium, magnesium) and aluminium salts.
- the or each A may independently be attached to the chain Z at any carbon atom of the chain.
- R 2 and R 3 are independently selected from H, unsubstituted alkyl, CH 2 OR 7 , CH 2 OCOR 7 , COOR 7 , CH 2 NHR 7 , CH 2 NHCOR 7 and CONHR 7 wherein R 7 is H or alkyl.
- R 1 is selected from H and unsubstituted alkyl. More preferably, R 1 , R 2 and R 3 are independently selected from H and unsubstituted alkyl. More preferably, R 1 and R 2 are H and R 3 is unsubstituted alkyl. It is further preferred that R 3 is methyl.
- R 1 , R 2 and R 3 are independently selected from H, unsubstituted alkyl, CH 2 OR 7 , CH 2 OCOR 7 , COOR 7 , CH 2 NHR 7 , CH 2 NHCOR 7 and CONHR 7 wherein R 7 is H or alkyl.
- R 1 , R 2 and R 3 are independently selected from H and unsubstituted alkyl. More preferably, R ! , R 2 and R 3 are H.
- the present invention provides compounds wherein A is Al.
- the present invention provides compounds wherein Z is (CH 2 ) m wherein m is 1 to 10.
- the present invention provides compounds wherein Z is a hydrocarbyl chain having from 2 to 10 carbon atoms, preferably from 2 to 6 carbon atoms, more preferably 2, 3 or 4 carbon atoms.
- the present invention provides compounds wherein Z is a hydrocarbyl chain having from 1 to 6 carbon atoms, preferably from 2 to 6 carbon atoms, more preferably 2, 3 or 4 carbon atoms.
- the saturated hydrocarbyl chain Z may be branched or unbranched, optionally substituted by one or more alkyl groups, and may be cyclic.
- cyclic means either that Z may comprise a cyclic hydrocarbyl group of from 3 to 10 carbon atoms, preferably 5, 6 or 7 carbon atoms; or that a cyclic group is present as a result of cyclisation of R 5 or R 6 onto Z; or that, where X is NR 4 and R 4 is alkyl, a cyclic group is present as a result of cyclisation of R 4 onto Z. It is preferred that a cyclic group formed as a result of cyclisation of R 4 , R 5 or R 6 onto Z is a 5, 6 or 7-membered ring.
- Z is an unbranched hydrocarbyl chain.
- the present invention provides compounds wherein X is O, S or a direct bond, more preferably X is O or a direct bond.
- R 4 is preferably alkyl
- R 4 when X is NR 4 and R 4 is alkyl, R 4 may be cyclized onto the chain defined as Z.
- R 4 may be cyclized onto the chain defined as Z.
- An example of a compound of formula (1) where R 4 is cyclized onto the chain defined as Z is:
- R 5 is preferably selected from H and C,. 10 alkyl. Where R s is C,. 10 alkyl, R 5 is preferably methyl. Most preferably, R 5 is H. It is preferred that at least one R 5 is H.
- the present invention provides compounds wherein n is 1 to 3, more preferably n is 1 or 2.
- R 5 is H
- OR 5 is positioned in the ortho or para position in the ring with respect to X. More preferably OR 5 is positioned in the para position with respect to X.
- n is greater than 1, it is preferred that the OR 3 groups are positioned ortho to each other to give, for example, a compound of formula:
- the or each R 6 is preferably independently selected from C,. 10 alkyl, preferably C M alkyl, most preferably methyl, isopropyl or t-butyl.
- the present invention provides compounds wherein p is 2, 3 or 4.
- alkyl groups represented by R 6 is/are preferably positioned ortho to OR 5 , preferably in the meta-position of the ring with respect to X to give, for example, a compound of formula:-
- alkyl groups represented by R 6 are preferably .positioned to give, for example where three R 6 are methyl, a compound of formula: -
- R 5 or R 6 can be cyclized on to the chain defined as Z to form a ring.
- An example of a compound of formula (1) where R 5 is cyclized on to the chain defined as Z and where X is a direct bond is:
- A is Al, R 1 and R 2 are H, R 3 is methyl, m is 2 or 3, X is a direct bond, R 5 is H, R 6 is t-butyl, n is 1 and p is 2.
- the compound of formula (1) is l-(3-(3,5-di-tert-butyl-4- hydroxyphenyl)propyl)-3-hydroxy-2-methyl-4(lH)-pyridinone (2a):
- A is Al, R 1 and R 2 are ⁇ , R 3 is methyl, m is 3, X is O, R 5 is ⁇ , R 6 is methyl, n is 2 and p is 4.
- the compound of formula (1) is l-(2-(2,3-dihydro-5-hydroxy-4,6,7- trimethylbenzofuran-2-yl)ethyl)-3-hydroxy-2-methyl-4(lH)-pyridinone (2b):
- the compounds of the present invention may be prepared using standard synthetic chemistry.
- a general method for the synthesis of compounds where q- ⁇ and A is a 3-hydroxy-4(lH)- pyridinone moiety comprises condensation of the primary amine of the respective antioxidant unit (3) with 3-benzyloxy-2-methyl-4-pyrone (4), followed by removal of the benzyl protecting group, as illustrated in Reaction Scheme 1.
- condensation of (4) with simple primary amines see Dobbin et al, J. Med. Chem., 1993, 36, 2448-2458).
- the primary amines, of the respective antioxidants, (3) can be prepared using standard synthetic chemistry.
- the -OH of the antioxidant unit can be optionally protected during synthetic manipulation (for example, as a benzyl ether). Deprotection to reveal the -OH of the antioxidant unit can be carried out simultaneously with removal of the benzyl protecting group of the hydroxy pyridone unit, in the last step of the sequence.
- an alternative electrophilic alkylating derivative of the antioxidant unit for example, mesylate or tosylate
- the primary halides, (mesylates and tosylates) of the antioxidants, (6) can be prepared using standard synthetic chemistry.
- the -OH of the antioxidant unit can be optionally protected during synthetic manipulation (for example, as a benzyl ether). Deprotection to reveal the -OH of the antioxidant unit can be carried out simultaneously with removal of the methyl protecting group of the hydroxy pyridone unit, in the last step of the sequence.
- the bis-primary amine (7) may be prepared using standard synthetic chemistry.
- Reaction Scheme 4 illustrates a method of preparation of bis-primary amine (8).
- a compound is an intermediate in the synthesis of a compound of the type exemplified as Example 11 herein.
- the bis-primary amine (8) may be prepared from bromide (9) via reaction with dimethylmalonate (in the presence of a suitable base, for example NaH) to produce the dimethylester, followed by reduction (using for example BH 3 .Me 2 S) to produce the diol (10).
- Diol (10) may then be converted to the dimesylate (using methanesulphonyl chloride and a suitable base, for example triethylamine), reacted with sodium azide, and reduced (using for example H 2 and Pd/C) to produce the bis-primary amine (8) (Palmer et al J. Med Chem., 1990, 33, 3008-3014).
- a suitable base for example triethylamine
- the bis-primary amine (8) may be prepared from the bis-diamide (11) via reduction (with for example lithium aluminium hydride, or borane), as illustrated in Reaction Scheme 5.
- the bis-amide (11) may be prepared using standard synthetic chemistry procedures.
- the bis-diamide (11) may be prepared from the benzyl bromide (9); via reaction with malonamide in the presence of a suitable base (for example NaOH in liquid ammonia) (Asami et al Sci. Rep. Res. Inst., 1957, 335-337); or alternatively via reaction with diethyl malonate in the presence of a suitable base (for example NaH in DMF) to produce the diester, followed by di-amidation (using for example ammonia).
- a suitable base for example NaOH in liquid ammonia
- a suitable base for example NaH in DMF
- bis-diamide (11) may be prepared from benzaldehyde (12), via reaction with diethylmalonate in the presence of a suitable base (for example piperidine in EtOH) to produce the diester olefin, followed by reduction of the olefin (using for example H 2 and Pd/C), and finally di-amidation (using for example ammonia in EtOH) (Sekiya et al. Chem. Pharm. Bull., 1964, 12, 674-677); or via reaction with malononitrile in the presence of a suitable base (for example piperidine in EtOH) to produce the dinitrile olefin (Gazit et al, J. Med.
- a suitable base for example piperidine in EtOH
- Reaction Scheme 7 illustrates a method of preparation of a bis-primary amine (13).
- a bis-primary amine 13
- Such a compound is an intermediate in the synthesis of a compound of the type exemplified as Example 12 herein.
- the bis-primary amine (13) may be prepared from aldehyde (12) via reaction with nitromethane in the presence of a suitable base (using for example catalytic butyl amine) to produce the dinitro compound (14) (Cassels et al. Rev. Latinoam. Quim. 1988, 1_9, 25-8), followed by reduction (with for example with lithium aluminium hydride, or H 2 and Pd/C, or H 2 and Raney-nickel).
- the bis-primary amine (13) may be prepared from aldehyde (12) via reaction with cyanoacetic acid in the presence of a suitable base (using for example pyridine and sodium acetate in toluene) to produce the dinitrile (Erion et al J. Med. Chem., 1993, 36, 3771-3783), followed by hydrolysis (using for example aqueous sulphuric acid) to produce the bis-amide (15), and finally Hofmann rearrangement (using for example NaOH and bromine) to produce the bis- primary amine (13) (Weinhardt et al. J. Med Chem., 1985, 28, 694-698). Reaction Scheme 7
- bis-primary amine (13) may be prepared from chloroamide (16) via reaction with sodium cyanide (in a suitable solvent such as DMF), followed by reduction (using for example lithium aluminium hydride) (Jahn et al, Can. J. Chem., 1988, 66, 123-131), as illustrated in Reaction Scheme 8.
- the compounds of the present invention may contain one or more asymmetric carbon atoms, so that the compounds exist in different stereoisomeric forms.
- the compounds can be, for example, racemates or optically active forms.
- the optically active forms can be obtained by resolution of the racemates or by asymmetric syntheses.
- the compounds of the present invention may also be prepared in a prodrug form wherein some or all the free -OH groups of the preferred compounds are derivatised (for example, via an ester, amide or phosphate bond) with a suitable group (the group may contain, for example, an alkyl, aryl, phosphate, sugar, amine, glycol, sulfonate or acid function) which is suitably labile so as it will be removed / cleaved (eg. by hydrolysis) to reveal the preferred compound sometime after administration or when exposed to the desired biological environment.
- a suitable group the group may contain, for example, an alkyl, aryl, phosphate, sugar, amine, glycol, sulfonate or acid function
- labile eg. by hydrolysis
- compounds of the present invention may also contain additional non-covalently linked components such as dextrans or cyclodextrins, which aid stability and dispersion, and decrease metabolism of the active ingredient.
- additional non-covalently linked components such as dextrans or cyclodextrins, which aid stability and dispersion, and decrease metabolism of the active ingredient.
- a compound of the present invention in the manufacture of a medicament for the treatment of a condition resulting in oxidative stress, particularly oxidative damage of the central nervous system.
- treatment includes prophylaxis.
- Diseases, disorders and medical treatments/procedures resulting in oxidative stress include: aging; acute intermittent porphyria; adriamycin-induced cardiomyopathy; AIDS dementia and HIV-l induced neurotoxicity; Alzheimer's disease; atherosclerosis; cateract; cerebral ischaemia; cerebral palsy; cerebral tumour; chemotherapy-induced organ damage; cisplatin-induced nephrotoxicity; coronary artery bypass surgery; diabetic neuropathy; Down's syndrome; drowning; epilepsy and post-traumatic epilepsy; Friedrich's ataxia; frontotemporal dementia; glaucoma; glomerulopathy; haemochromatosis; haemodialysis; haemolysis; haemolytic uraemic syndrome (Weil's disease); haemorrhagic stroke; heart attack and reperfusion injury; Huntington's disease; Lewy body disease; intermittent claudication; ischaemic stroke; inflammatory bowel disease; macular
- compounds of the present invention may also be used to potentiate the effects of other treatments, for example to potentiate the neuroprotective effects of brain derived nerve growth factor.
- the invention is particularly directed to conditions which induce oxidative damage of the central nervous system, including acute and chronic neurological disorders such as traumatic brain injury, spinal cord injury, cerebral ischaemia, stroke (ischaemic and haemorragic), subharrachnoid haemorrage/cerebral vasospasm, cerebral tumour, Alzheimer's disease, Huntington's disease, Parkinson's disease, Friedrich's ataxia, motor
- the invention further provides a method of treating a condition resulting in oxidative stress, particularly oxidative damage of the central nervous system, comprising administering to a patient in need of such treatment an effective dose of a compound of the 20 present invention.
- the invention further provides a pharmaceutical composition comprising a compound of the present invention in combination with a pharmaceutically acceptable carrier or excipient and a method of making such a composition comprising combining a compound 25 of the present invention with a pharmaceutically acceptable carrier or excipient.
- Compounds of the present invention may be administered in a form suitable for oral use, for example a tablet, capsule, granule powder, aqueous or oily solution, suspension or emulsion; for topical use including transmucosal and transdermal use, for example a cream, 30 ointment, gel, aqueous or oil solution or suspension, salve, patch or plaster; for nasal use, for a example a snuff, nasal spray or nasal drops; for vaginal or rectal use, for example a suppository; for administration by inhalation, for example a finely divided powder or a liquid aerosol; for sub-lingual or buccal use, for example a tablet or capsule; or for parenteral use (including intravenous, subcutaneous, intramuscular, intravascular, intrathecal or infusion), for example a sterile aqueous or oil solution or suspension.
- parenteral use including intravenous, subcutaneous, intramuscular, intravascular, intrathecal or infusion
- compositions may be prepared in a conventional manner using conventional excipients, using standard techniques well known to those skilled in the art of pharmacy.
- the compound is administered orally for chronic disorders such as Alzheimer's and Parkinson's disease, and intravenously for acute disorders such as stroke and TBI.
- the compounds of the invention will generally be provided in the form of tablets or capsules or as an aqueous solution or suspension.
- Tablets for oral use may include the active ingredient mixed with pharmaceutically acceptable excipients such as inert diluents, disintegrating agents, binding agents, lubricating agents, sweetening agents, flavouring agents, colouring agents and preservatives.
- suitable inert diluents include sodium and calcium carbonate, sodium and calcium phosphate, cyclodextrin, and lactose, while corn starch and alginic acid are suitable disintegrating agents.
- Binding agents may include starch and gelatin, while the lubricating agent, if present, will generally be magnesium stearate, stearic acid or talc. If desired, the tablets may be coated with a material such as glyceryl monostearate or glyceryl distearate, to delay absorption in the gastrointestinal tract.
- Capsules for oral use include hard gelatin capsules in which the active ingredient is mixed with a solid diluent, and soft gelatin capsules wherein the active ingredient is mixed with water or an oil such as peanut oil, liquid paraffin or olive oil.
- the compounds of the invention will generally be provided in sterile aqueous solutions or suspensions, buffered to an appropriate pH and isotonicity.
- Suitable aqueous vehicles include Ringer's solution and isotonic sodium chloride.
- Aqueous suspensions according to the invention may include suspending agents such as cellulose derivatives, lipids, sodium alginate, polyvinyl- pyrrolidone, cyclodextrins, gum tragacanth, polyethylene glycol, propylene glycol, N,N- dimethylacetamide, cremophors, polysorbates, liposomes and wetting agents such as lecithin.
- l-(3-(3,5-di-tert-butyl-4-hydroxyphenyl)propyl)-3-hydroxy- 2-methyl-4(lH)-pyridinone (2a) is particularly soluble in hydroxypropyl- ⁇ -cyclodextrin.
- Suitable preservatives for aqueous suspensions include ethyl and n-propyl p- hydroxybenzoate.
- dosage levels used may vary over quite a wide range depending upon the compound used, the severity of the symptoms exhibited by the patient and the patient's body weight.
- Figure 1 shows the protective effect of a compound of the present invention on cerebellar granular cells exposed to IAA-induced oxidative damage.
- Figure 2 shows the effect of compounds of the present invention on intracellular oxidation of dichlorodihydrofluorescin (DCF ⁇ ) to dichlorofluorecin (DCF). IAA-stimulated fluorescence values are given as a function of concentration of the test compound.
- Figure 3 and Figure 4 show the in vivo activity of compounds of the present invention in the malonic acid lesion model of oxidative stress.
- Methanesulphonic acid (175 ⁇ L, 2.7 mmol) was added dropwise to l-(3-(3,5-di-tert-butyl- 4-hydroxyphenyl)propyl)-3-hydroxy-2-methyl-4(lH)-pyridinone (1.0 g, 2.7 mmol) in Et j O (50 mL) and C ⁇ 2 C1 2 (50 mL). The mixture was stirred for 1.5 h, concentrated in vacuo, suspended in CHC1 3 and the solid collected by filtration to give the title compound (1.1 g,
- BH 3 -Me 2 S (130 mmol) is added to a mixture of dimethyl 2-(3,5-di-tert-butyl-4- hydroxybenzyl)malonate (40 mmol) and THF (100 mL) under Ar. The resulting solution is heated under reflux for 40 h. MeOH is added slowly to the cooled solution to destroy excess reagent. The mixture is diluted with brine, extracted with EtOAc and concentrated in vacuo. The residue is purified by chromatography [SiO 2 ; EtOAc-Hexane] to give the product.
- reaction is cooled, adjusted to pH 3-4 with 1.0-M HCl, concentrated in vacuo, extracted with CHC1 3 , dried (MgSO 4 ), concentrated in vacuo and purified by chromatography [SiO,; CH 2 Cl 2 -MeOH (95:5)] to give the product in low yield.
- Methanesulphonic acid (175 ⁇ L, 2.7 mmol) is added dropwise to l-(3-(3,5-di-tert-butyl-4- hydroxyphenyl)-2-(l,4-dihydro-3-hydroxy-2-methyl-4-oxo-l-pyridinylmethyl)propyl)-3- hydroxy-2-methyl-4(lH)-pyridinone (1.3 mmol) in Et,O (50 mL) and C ⁇ 2 C1 2 (50 mL). The mixture is stirred for 1.5 h, concentrated in vacuo, suspended in CHC1 3 and the solid collected by filtration to give the title compound.
- Methanesulphonic acid (2 eq) is added dropwise to l-(2-(3,5-di-tert-butyl-4- hydroxyphenyl)-2-( 1 ,4-dihydro-3 -hydroxy-2-methyl-4-oxo- 1 -pyridinylmethyl)ethyl)-3- hydroxy-2-methyl-4(lH)-pyridinone in Et 2 O and C ⁇ 2 C1 2 .
- the mixture is stirred for 1.5 h, concentrated in vacuo, suspended in CHC1 3 and the solid collected by filtration to give the title compound.
- Lipid peroxidation in rat brain homogenates is a general procedure used to measure the antioxidant capacity of molecules in a biological environment (Das N.P. and Ratty A.K., Biochem. Med. Metab. Biol. 1987, 37, 256-264). Compounds of the present invention have been shown to be potent inhibitors of lipid peroxidation.
- Iodoacetate via its alkylation of glyceraldehyde-3-phosphate dehydrogenase (GAPDH), is a potent inhibitor of glycolysis and hence energy production in cells.
- GPDH glyceraldehyde-3-phosphate dehydrogenase
- the compounds of the present invention have been shown to protect cerebellar granule cells from this chemical induced oxidative stress. Furthermore, synergistic behaviour has been demonstrated for the compound of Example 1 over the combination of a single action Fe- chelator and single action antioxidant.
- Malonic acid is an inhibitor of succinate dehydrogenase. It depletes intracellular ATP production, and intrastriatal injection has previously been demonstrated to cause a NMDA receptor mediated lesion (Greene et al, J. Neurochem. 1993, 61, 1151-5). Compounds of the present invention have shown neuroprotective ability in this animal model of oxidative stress.
- Rat cortex was homogenised in 20 volumes of ice cold 0.32-M sucrose and centrifuged at 1,000 g for 10 min. The pellet was discarded whilst the resulting supernatant was centrifuged at 15,000 g for 20 min at 4°C to yield p2 pellets. The pellet was resuspended in ice-cold 50.0-mM phosphate buffer and centrifuged at 30,000 g for 20 min at 4°C. The pellet was resuspended in 30 vols of 50.0-mM phosphate buffer and used immediately in the assay.
- Assays contained 500- ⁇ M L-ascorbic acid to induce lipid peroxidation, plus various concentrations of test compound, with the tissue preparation in a total volume of 500 ⁇ L. This was incubated at 37°C for 30 min. Lipid peroxidation was measured by adding to the reaction mixture, 300 ⁇ L 40% (w/v) trichloroacetic acid, 150 ⁇ L 5.0-M HCl and 300 ⁇ L 2%> (w/v) 2-thiobarbituric acid (TBA). Samples were then heated at 90°C in a water bath for 15 min, and centrifuged at 15,000 g for 10 min. The pink colour of the supernatant was assessed spectrophotometrically at a wavelength of 532 nm.
- MDA malondialdehyde
- IC 50 values ( ⁇ M) and presented in Table 1 below.
- the IC 50 values show the concentration of test compound required to inhibit the lipid peroxidation by 50%>. Table 1.
- CGC cerebellar granule cell
- IAA Iodoacetate
- BSS balanced salt solution
- HEPES N-[2-hydroxyethyl]piperazine-N ' -[2-ethanesulfonic acid]
- HEPES N-[2-hydroxyethyl]piperazine-N ' -[2-ethanesulfonic acid]
- any neuroprotective agents were made up in pre-warmed tissue culture media and allowed to equilibrate in a controlled environment (5%o CO 2 , 95%> air).
- the assay was initiated by aspiration of the maintenance media, which was replaced by either BSS (control) or 30- ⁇ M IAA in BSS, both solutions containing 10- ⁇ M of the NMDA receptor antagonist MK-801.
- the exposure to IAA was for 30 min only at 37 °C, after which time the BSS was aspirated and replaced with fresh, pre-equilibriated maintenance media containing various concentrations of test compound. All conditions were performed at least in duplicate in each 96 well plate. - The final volume for each well was always 200- ⁇ L.
- Results are expressed as EC 50 values ( ⁇ M) and presented in Table 2 below.
- Figure 1 shows the protective effect from 30- ⁇ M IAA toxicity by 1- ⁇ M concentrations of test compound.
- CGC are exposed to 30- ⁇ M IAA for 30 mins in a physiological salt solution. This is replaced with maintenance media containing 1- ⁇ M test compound and the cells are then tested for viability 24 hrs later.
- the compounds tested were Example 1, compound I (below), compound ⁇ (below) and a mixture of compounds I and II
- DCFH-DA oxidant-sensitive fluorescent dye 2',7'-dichlorodihydrofluorescein diacetate
- DCFH-DA oxidant-sensitive fluorescent dye 2',7'-dichlorodihydrofluorescein diacetate
- Results are expressed as EC 50 values ( ⁇ M) and presented in Table 3 below.
- the EC 50 value gives the effective concentration of test compound required to block the oxidation of DCFH to DCF by 50%.
- the EC 50 value is derived from Figure 2 by extrapolating from the point at which the fluoresence value is reduced to 50% of its original maximum value.
- Malonic acid is a competitive inhibitor of succinate dehydrogenase, a key enzyme in both the tricarboxyhc acid cycle and oxidative phosphorylation.
- Injection of malonic acid into the striatum causes ATP depletion, resulting in an excitotoxic lesion (Greene et al, J. Neurochem., 1993, 61, 1151-1154).
- 2 ⁇ L of a 0.5-M malonic acid solution is injected into the right striatum of rats, with or without test compounds. 24 hours after surgery the animals are sacrificed and the size of the lesion measured using TTC histochemistry.
- Example 1 The observed activity of the compounds of Example 1 and Example 7 are displayed in Figures 3 and 4, respectively.
- 2.2 ng of the compound of Example 1 is the equivalent of 2 ⁇ L of a 3.0- ⁇ M solution.
- 7.4 ng of the compound of either Example 1 or Example 7 is the equivalent of 2 ⁇ L of a 10.0- ⁇ M solution.
- 74 ng of the compound of Example 7 is the equivalent of 2 ⁇ L of a 100.0- ⁇ M solution.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Psychology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000518950A JP2001521924A (en) | 1997-10-31 | 1998-10-30 | Ortho-hydroxypyridinone derivatives as iron chelators and antioxidants |
EP98950227A EP1027335A1 (en) | 1997-10-31 | 1998-10-30 | Ortho-hydroxypyridinone derivatives as iron chelating and antioxidant agents |
AU96380/98A AU9638098A (en) | 1997-10-31 | 1998-10-30 | Ortho-hydroxypyridinone derivatives as iron chelating and antioxidant agents |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9723078.3A GB9723078D0 (en) | 1997-10-31 | 1997-10-31 | Chemical compounds |
GB9723078.3 | 1997-10-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1999023075A1 true WO1999023075A1 (en) | 1999-05-14 |
Family
ID=10821419
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB1998/003244 WO1999023075A1 (en) | 1997-10-31 | 1998-10-30 | Ortho-hydroxypyridinone derivatives as iron chelating and antioxidant agents |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1027335A1 (en) |
JP (1) | JP2001521924A (en) |
AU (1) | AU9638098A (en) |
GB (1) | GB9723078D0 (en) |
WO (1) | WO1999023075A1 (en) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1006112A1 (en) * | 1998-12-01 | 2000-06-07 | Cerebrus Pharmaceuticals Limited | 3-Hydroxy-2(1H)-pyridinone or 3-hydroxy-4(1H)-pyridinone derivatives useful as reactive oxygen species (ROS) scavengers |
EP1006108A1 (en) * | 1998-12-01 | 2000-06-07 | Cerebrus Pharmaceuticals Limited | 3-Hydroxy-2(1H)-pyridinone or 3-hydroxy-4(1H)-pyridinone derivatives useful as reactive oxygen species (ROS) scavengers |
US6825204B2 (en) | 2002-02-05 | 2004-11-30 | Bristol-Myers Squibb Company | N-substituted 3-hydroxy-4-pyridinones and pharmaceuticals containing thereof |
US7998986B2 (en) | 2001-12-21 | 2011-08-16 | Exelixis Patent Company Llc | Modulators of LXR |
US8013001B2 (en) | 2001-12-21 | 2011-09-06 | Exelixis, Inc. | Modulators of LXR |
US20130005744A1 (en) * | 2010-03-04 | 2013-01-03 | Scott Wolkenberg | Inhibitors of catechol o-methyl transferase and their use in the treatment of psychotic disorders |
WO2019205843A1 (en) * | 2018-04-26 | 2019-10-31 | 嘉兴维眸生物科技有限公司 | Anti-inflammatory compound and preparation and use thereof |
WO2021143048A1 (en) * | 2020-01-19 | 2021-07-22 | 杭州泽德医药科技有限公司 | 3,4-dihydroxy-n-(1'-benzyl-2'-hydroxyethyl)-2-methylpyridine chloride, and preparation and application thereof |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8058442B2 (en) | 2002-11-07 | 2011-11-15 | Technion Research And Development Foundation Ltd. | Neuroprotective iron chelators and pharmaceutical compositions comprising them |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0120670A1 (en) * | 1983-03-24 | 1984-10-03 | National Research Development Corporation | Iron III complexes of hydroxypyridones, and their pharmaceutical compositions |
WO1993010822A1 (en) * | 1991-12-05 | 1993-06-10 | The Du Pont Merck Pharmaceutical Company | TECHNETIUM-99 m COMPLEXES WITH N-SUBSTITUTED 3-HYDROXY-4-PYRIDINONES |
EP0768302A2 (en) * | 1995-09-29 | 1997-04-16 | Novartis AG | Hydroxypyridinones |
US5624901A (en) * | 1994-04-15 | 1997-04-29 | The Regents Of The University Of California | 3-hydroxy-2(1H)-pyridinone chelating agents |
WO1998025905A2 (en) * | 1996-12-10 | 1998-06-18 | Cenes Limited | Therapeutic antioxidants for alzheimer's disease |
-
1997
- 1997-10-31 GB GBGB9723078.3A patent/GB9723078D0/en not_active Ceased
-
1998
- 1998-10-30 EP EP98950227A patent/EP1027335A1/en not_active Withdrawn
- 1998-10-30 AU AU96380/98A patent/AU9638098A/en not_active Abandoned
- 1998-10-30 JP JP2000518950A patent/JP2001521924A/en not_active Withdrawn
- 1998-10-30 WO PCT/GB1998/003244 patent/WO1999023075A1/en not_active Application Discontinuation
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0120670A1 (en) * | 1983-03-24 | 1984-10-03 | National Research Development Corporation | Iron III complexes of hydroxypyridones, and their pharmaceutical compositions |
WO1993010822A1 (en) * | 1991-12-05 | 1993-06-10 | The Du Pont Merck Pharmaceutical Company | TECHNETIUM-99 m COMPLEXES WITH N-SUBSTITUTED 3-HYDROXY-4-PYRIDINONES |
US5624901A (en) * | 1994-04-15 | 1997-04-29 | The Regents Of The University Of California | 3-hydroxy-2(1H)-pyridinone chelating agents |
EP0768302A2 (en) * | 1995-09-29 | 1997-04-16 | Novartis AG | Hydroxypyridinones |
WO1998025905A2 (en) * | 1996-12-10 | 1998-06-18 | Cenes Limited | Therapeutic antioxidants for alzheimer's disease |
Non-Patent Citations (11)
Title |
---|
CHEMICAL ABSTRACTS, vol. 121, no. 21, 21 November 1994, Columbus, Ohio, US; abstract no. 248239, XP002093474 * |
CHEMICAL ABSTRACTS, vol. 121, no. 9, 29 August 1994, Columbus, Ohio, US; abstract no. 99755, XP002093475 * |
CHEMICAL ABSTRACTS, vol. 126, no. 22, 2 June 1997, Columbus, Ohio, US; abstract no. 287657, XP002093473 * |
CHEMICAL ABSTRACTS, vol. 126, no. 7, 17 February 1997, Columbus, Ohio, US; abstract no. 84159, XP002093472 * |
FILE REGISTRY (DATABASE STN CAS) * |
J.J. MOLENDA ET AL, CHEM. RES. TOXICOL., vol. 7, no. 6, 1994, pages 815 - 822 * |
JOHN JOSEF MOLENDA ET AL., J. INORG. BIOCHEM., vol. 55, no. 2, 1994, pages 131 - 146 * |
M. STREATER ET AL., JOURNAL OF MEDICINAL CHEMISTRY, vol. 33, 1990, WASHINGTON US, pages 1749 - 1755, XP002064972 * |
M.M. JONES ET AL., ARZNEIMITTEL FORSCHUNG DRUG RESEARCH., vol. 46, no. 12, 1996, AULENDORF DE, pages 1158 - 1162 * |
P.K. SINGH ET AL., ARZNEIMITTEL FORSCHUNG DRUG RESEARCH., vol. 47, no. 3, 1997, AULENDORF DE, pages 311 - 315 * |
P.S. DOBBIN ET AL., JOURNAL OF MEDICINAL CHEMISTRY, vol. 36, 1993, WASHINGTON US, pages 2448 - 2458, XP002064973 * |
Cited By (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1006112A1 (en) * | 1998-12-01 | 2000-06-07 | Cerebrus Pharmaceuticals Limited | 3-Hydroxy-2(1H)-pyridinone or 3-hydroxy-4(1H)-pyridinone derivatives useful as reactive oxygen species (ROS) scavengers |
EP1006108A1 (en) * | 1998-12-01 | 2000-06-07 | Cerebrus Pharmaceuticals Limited | 3-Hydroxy-2(1H)-pyridinone or 3-hydroxy-4(1H)-pyridinone derivatives useful as reactive oxygen species (ROS) scavengers |
US7998986B2 (en) | 2001-12-21 | 2011-08-16 | Exelixis Patent Company Llc | Modulators of LXR |
US8013001B2 (en) | 2001-12-21 | 2011-09-06 | Exelixis, Inc. | Modulators of LXR |
US6825204B2 (en) | 2002-02-05 | 2004-11-30 | Bristol-Myers Squibb Company | N-substituted 3-hydroxy-4-pyridinones and pharmaceuticals containing thereof |
US6932960B2 (en) | 2002-02-05 | 2005-08-23 | Bristol-Myers Squibb Pharma Company | N-substituted 3-hydroxy-4-pyridinones and pharmaceuticals containing thereof |
US20130005744A1 (en) * | 2010-03-04 | 2013-01-03 | Scott Wolkenberg | Inhibitors of catechol o-methyl transferase and their use in the treatment of psychotic disorders |
AU2011223976B2 (en) * | 2010-03-04 | 2015-05-21 | Merck Sharp & Dohme Corp. | Inhibitors of catechol O-methyl transferase and their use in the treatment of psychotic disorders |
US9309199B2 (en) | 2010-03-04 | 2016-04-12 | Merck Sharp & Dohme Corp. | Inhibitors of catechol O-methyl transferase and their use in the treatment of psychotic disorders |
CN110407741A (en) * | 2018-04-26 | 2019-11-05 | 嘉兴维眸生物科技有限公司 | A kind of anti-inflammatory compound and its preparation and application |
WO2019205843A1 (en) * | 2018-04-26 | 2019-10-31 | 嘉兴维眸生物科技有限公司 | Anti-inflammatory compound and preparation and use thereof |
TWI701239B (en) * | 2018-04-26 | 2020-08-11 | 大陸商嘉興維眸生物科技有限公司 | Anti-inflammatory compound and its preparation and application |
EP3777979A4 (en) * | 2018-04-26 | 2021-08-04 | E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd | Anti-inflammatory compound and preparation and use thereof |
RU2759626C1 (en) * | 2018-04-26 | 2021-11-16 | И-Нишиэйт Биофармасьютикалс (Ханчжоу) Ко., Лтд | Anti-inflammatory compound, production and application thereof |
US11440886B2 (en) | 2018-04-26 | 2022-09-13 | E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd. | Anti-inflammatory compound, and preparation and use thereof |
CN110407741B (en) * | 2018-04-26 | 2023-03-21 | 启元生物(杭州)有限公司 | Anti-inflammatory compound and preparation and application thereof |
IL278165B1 (en) * | 2018-04-26 | 2024-06-01 | Vivavision Biotech Inc | Anti-inflammatory compound and preparation and use thereof |
IL278165B2 (en) * | 2018-04-26 | 2024-10-01 | Vivavision Biotech Inc | Anti-inflammatory compound and preparation and use thereof |
WO2021143048A1 (en) * | 2020-01-19 | 2021-07-22 | 杭州泽德医药科技有限公司 | 3,4-dihydroxy-n-(1'-benzyl-2'-hydroxyethyl)-2-methylpyridine chloride, and preparation and application thereof |
JP2023507025A (en) * | 2020-01-19 | 2023-02-20 | 杭州▲澤▼徳医▲薬▼科技有限公司 | 3,4-dihydroxy-N-(1'-benzyl-2'-hydroxyethyl)-2-methylpyridinium chloride, its preparation and use |
Also Published As
Publication number | Publication date |
---|---|
GB9723078D0 (en) | 1998-01-07 |
AU9638098A (en) | 1999-05-24 |
JP2001521924A (en) | 2001-11-13 |
EP1027335A1 (en) | 2000-08-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1006112A1 (en) | 3-Hydroxy-2(1H)-pyridinone or 3-hydroxy-4(1H)-pyridinone derivatives useful as reactive oxygen species (ROS) scavengers | |
CA2417475C (en) | Composes azabicycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacterien | |
US7410956B2 (en) | Caspase inhibitor prodrugs | |
KR20170008320A (en) | Nicotinamide riboside analogs and pharmaceutical compositions and uses thereof | |
JP2002322095A (en) | Combination as medicine for therapy of apoplexy and traumatic brain impediment | |
GB2345058A (en) | Hydroxypyridone compounds useful in the treatment of oxidative damage to the central nervous system | |
PL154186B1 (en) | Method for manufacturing arylic derivatives of the hydroxamic acid | |
WO2014093231A2 (en) | Hybrid compounds and methods of making and using the same | |
JP2004518628A (en) | Nitrogen-containing compounds and their use as glycine transport inhibitors | |
KR101539588B1 (en) | (6,7-dihydro-2-nitro-5h-imidazol[2,1-b] [1,3]oxazin-6-yl) amide compounds, preparation methods and uses thereof | |
EP2242492B1 (en) | Antitumoral agents with a benzophenanthridine structure and formulations containing them | |
CN116724023A (en) | Cannabinoid derivatives as pharmaceutically active compounds and process for their preparation | |
EP1027335A1 (en) | Ortho-hydroxypyridinone derivatives as iron chelating and antioxidant agents | |
EP1006108A1 (en) | 3-Hydroxy-2(1H)-pyridinone or 3-hydroxy-4(1H)-pyridinone derivatives useful as reactive oxygen species (ROS) scavengers | |
US7049309B2 (en) | 3-Thia-4-arylquinolin-2-one potassium channel modulators | |
US11434198B2 (en) | Compounds and methods for the treatment of neurodegenerative diseases | |
EP0499882A1 (en) | Pharmaceutical compositions containing N-acetyl-cysteine derivatives useful for the treatment of cataracts | |
JPH09507846A (en) | Phenylmethylhexanamide and its use | |
US8680279B2 (en) | Compounds for the treatment of neurological disorders | |
JP2024091930A (en) | D-amphetamine compound, composition, as well as process for producing and use thereof | |
RU2685502C2 (en) | Therapeutic agents for use in preventing and/or treating hyperkinetic motor disorders | |
EP0339600A2 (en) | Polycyclic amine derivatives useful as cerebrovascular agents | |
KR101115196B1 (en) | 2-aminobenzoyl derivatives | |
PL208284B1 (en) | Benzo [g] quinoline derivatives for treating glaucoma and myopia | |
EP2588109A1 (en) | Use of kynurenic acid amide derivatives for the treatment of huntington's disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1998950227 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09530454 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1998950227 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
NENP | Non-entry into the national phase |
Ref country code: CA |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1998950227 Country of ref document: EP |